Cardarine (GW-501516) is a peroxisome proliferator-activator receptor-delta agonist for the potential treatment of dyslipidemia. Cardarine has been investigated for the treatment of Obesity, Lipid Disorders, and Cardiovascular Disease.
- Mechanism
- Curator reviewed
This drug regulates fatty acid oxidation in several tissues, such as skeletal muscle and adipose tissue. Overexpression of PPARdelta using a transgenic murine model promotes an increase of muscle oxidative capability. It also plays a major role in the metabolic adaptations to western diet characterized by an excessive amount of saturated fat.
- Primary indication
- Investigated for use/treatment in hyperlipidemia.Curator reviewed
- Formula / weight
- C21H18F3NO3S2 · 453.498 g/mol (avg)
- Code names
- GSK-516 · GW-1516 · GW-501516
Resolves to
YDBLKRPLXZNVNB-UHFFFAOYSA-NSMILESCC1=C(CSC2=CC(C)=C(OCC(O)=O)C=C2)SC(=N1)C1=CC=C(C=C1)C(F)(F)FWhat you can answer from here — as of June 15, 2026
Which drugs share a target with Cardarine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account